A proportion of patients with aplastic anemia who are treated with immunosuppressive therapy develop clonal hematologic disorders, including post-aplastic anemia myelodysplastic syndrome. Many will proceed to allogeneic hematopoietic stem cell transplantation. We identified 123 patients with post-aplastic anemia myelodysplastic syndrome who from 1991 through 2011 underwent allogeneic hematopoietic stem cell transplantation, and in a matchedpair analysis compared outcomes to that in 393 patients with de novo myelodysplastic syndrome.
Introduction
Immunosuppressive therapy (IST) and hematopoietic stem cell transplantation (HSCT) are two major treatment strategies for patients with aplastic anemia (AA). While in most patients AA is immune-mediated and amenable to IST, younger patients with HLA identical siblings often undergo HSCT as first line therapy. Older individuals, on the other hand, and those without HLA matched related donors generally are given IST, typically with antithymocyte globulin (ATG) with or without the addition of cyclosporine. 1, 2 Response rates with IST have ranged from 40% to 70%, and many responding patients are surviving long-term with normal or close to normal blood cell counts, not requiring further therapy. [3] [4] [5] However, some patients, particularly among those who do not achieve sustained responses to IST, will show clonal evolution and present clinically with manifestations of paroxysmal nocturnal hemoglobinuria (PNH) or myelodysplastic syndrome (post-AA MDS) that may evolve to acute myeloid leukemia. 6 Transformation to MDS has been reported in 1.7%-15% of patients over observation periods of 5-11 years. 7 Improvements of supportive care allow for prolonged survival of non-responding patients, even without HSCT, and the evolution of clonal hematopoietic disorders.
The pathogenesis of MDS (or Acute Myeloid Leukemia) in AA patients may be related to immune dysregulation, possibly enhanced by IST, and increased growth factor drive in response to the proliferative demands during the disease course. 7 Excessive telomere shortening leading to acquisition of chromosomal instability may contribute to clonal evolution. 8 It is not clear whether MDS developing on that background differs from de novo MDS. However, immunedysregulation and pro-inflammatory signals associated with the immune mechanism of AA may lead to a marrow environment in post-AA MDS patients, which differs from that in patients with de novo MDS. These differences may affect the prognosis and may impact the outcome of HSCT.
Allogeneic HSCT is a powerful therapeutic option for patients with MDS, including those with "secondary" MDS, be it due to prior cytotoxic therapy or related to an antecedent hematological disorder such as AA. [9] [10] [11] [12] A previous analysis of transplant outcome in patients with therapy-related MDS showed survival rates of 19-21% at 5 years, depending on disease status at transplantation 10 while another study reported survival rates of 20-48% at 3 years.
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These studies focused on MDS patients who had received prior cytotoxic chemotherapy or radiation for various malignant diseases. A recent study in 17 children with AA who developed MDS or AML following IST reported a 5-year event-free survival of 41%. 13 However, there is no large-scale study of transplantation for post-AA MDS, and no data comparing results to patients with de novo MDS. Thus, in the present study, we analyzed transplant outcomes of post-AA MDS patients, carried out a matched-pair analysis including patients with de novo MDS, and determined prognostic factors for transplant outcome.
Methods

Study population
In Cases of marrow failure/AA possibly associated with constitutional/inherited disorders were excluded. The time interval from the diagnosis of AA to the establishment of the diagnosis of MDS was 4 -491 (median 34) months. The MDS categories comprised refractory anemia (RA), refractory anemia with ring sideroblasts (RARS), refractory anemia with excess blasts (RAEB), and refractory anemia with excess blasts in transformation (RAEB-t). The data bases did not allow for categorization according to the WHO classification, nor was it possible in this retrospective analysis to categorize patients according to the recently proposed 5 cytogenetic risk groups as used in the revised International Prognostic Scoring System (IPSS-R). 14 Patients with AML (>30% marrow myeloblasts) and CMML were excluded. We conducted a matched pair analysis, matching cases to control on factors shown to influence transplantation outcomes.
Overall 1,473 patients with de novo MDS were reported to the CIBMTR during the study period.
Excluded were patients with MDS related to cytotoxic therapy, Fanconi anemia and other inherited marrow failure syndromes. Cases were matched to controls from this cohort for age (< 10 years vs. , and conditioning regimen intensity (myeloablative vs. reduced intensity). Cases and controls were matched to their respective age as close as possible: the difference in age of cases and controls was 0 -1 year for 56%, 2 -5 years for 30%, and 6 -10 years for the remaining 14%. For this latter sub-group the median age for cases was 23 years, compared to 29 years for controls.
Definitions
Cytogenetic risk was graded into good, intermediate, and poor, based on the IPSS. 14 Time of engraftment was defined as the first of 3 consecutive days with neutrophil counts that exceeded 0.5 x10 9 /L. Acute and chronic GVHD were defined and graded according to standard criteria. 15, 16 Overall Survival (OS) was defined as survival irrespective of disease status, and
Relapse-Free Survival (RFS) as survival without evidence of relapse at any point in time.
Relapse Incidence (RI) was defined as cumulative incidence of disease recurrence and NonRelapse Mortality (NRM) was defined as the occurrence of death without prior evidence of relapse.
Statistical analysis
The probabilities of hematopoietic recovery, acute and chronic GVHD, NRM and relapse were calculated using the cumulative incidence estimator. 17 The probabilities of OS and RFS were calculated with the Kaplan-Meier estimator. 18 Cox multivariate models 19 were built to test whether differences in outcome existed between the groups, adjusting for other factors that might influence outcome after HSCT. 
Results
Patient, disease, and transplant characteristics
Patient and disease characteristics of post-AA MDS and de novo MDS patients are summarized in Table 1 
P=0.003).
Engraftment and GVHD
Hematologic recovery and graft failure rates did not differ between the groups. The median time to neutrophil engraftment was 18 days for post-AA MDS, and 17 days for de novo MDS.
The day-28 cumulative incidence of neutrophil recovery was 87% (95% CI 79 -92) for post-AA MDS and 89% (95% CI 85 -92) for de novo MDS (P=0.51).
There was a trend towards higher cumulative incidence of GVHD among post-AA MDS patients but the difference did not reach statistical significance. The day-100 cumulative incidence of grades II-IV acute GVHD was 52% (95% CI 43 -61) and 47% (95% CI 42 -52), respectively (P=0.29; Figure 1A) , and the 5-year cumulative incidence of chronic GVHD was 55% (95% CI 45 -64) and 46% (95% CI 41 -51), respectively (P=0.11; Figure 1B ).
Relapse and Non-Relapse Mortality
With a median follow-up of 4 years, the 5-year cumulative incidence of relapse was 14% for post-AA MDS patients and 20% for de novo MDS (Figure 2A) . Table 3 ). The causes of NRM did not differ significantly between groups and were mainly GVHD, infection, and regimen-related toxicity ( Table 4) . There was a suggestion that post-AA MDS patients died more frequently from GVHD and infection than did de novo MDS patients. Graft failure did not significantly contribute to NRM in either group.
Cytogenetic risk was a significant predictor for NRM (P=0.01).
Relapse-free and Overall Survival
RFS (46% vs. 47%; P=0.91, Figure 2C ) and OS (49% for both groups; P=0.98, Figure 2D) were similar for both groups; the lower relapse risk among post-AA MDS patients was counterbalanced by a slightly higher NRM, although this difference did not attain the level of significance set for this study. 
Subset Analyses
In addition, we performed two subset analyses, one addressing the potential impact of the transplant period, and one aimed at delineating possible differences between pediatric and adult patients. In the first subset analysis, the study population was restricted to patients transplanted between 2000 and 2011 to exclude the possibility that the effects of recent changes in transplantation strategies on outcome may have been obscured by the inclusion of patients transplanted over the course of two decades. Consistent with the main analysis, there were no differences in overall survival (HR 0.87, 95% CI 0.59 -1.29, p=0.49), non-relapse mortality (HR 
Discussion
A large proportion of patients with post-AA MDS were transplanted successfully from related or unrelated donors, with a 5-year RFS of 46%, and 5-year OS of 49%, success rates similar to those in "matched" patients with de novo MDS, even after adjusting for other potential prognostic factors. While there was a clinical impression that patients with post-AA MDS relapsed less frequently (P=0.05 in univariate analysis), once pre-transplant therapy (administered after the diagnosis of MDS was established) was included in the analysis, there was no significant difference between the two cohorts. As there was a trend in the reverse direction for NRM, survival rates for the two cohorts were basically identical. Higher NRM among patients with post-AA MDS could have been due to a longer overall disease course (AA followed by MDS), leading to the development of additional comorbidities. Also, the different pathogenesis and an altered immune-environment in post-AA MDS compared to patients with de novo MDS might contribute to differences in the various endpoints. One might further speculate that there could have been an enrichment for patients with shortened telomeres in the post-AA interest as recent studies suggest that shorter telomeres were independently associated with higher NRM in patients with hematologic malignancies. 20 We did not include GVHD, a post-transplant risk factor, in multivariate analysis since the study was focused on pre-transplant variables. There was a trend towards higher cumulative incidence rates of both acute and chronic GVHD in post-AA MDS, which may have been related to a higher proportion of HLA-mismatched unrelated donor transplants, a pattern that would be consistent with the observed higher rate of NRM and lower incidence of relapse among post-AA MDS patients due to a stronger graft-versus MDS effect.
The prognosis of therapy-related MDS evolving after chemotherapy or radiotherapy is worse than that of de-novo MDS, presumably because of the higher frequency of poor risk cytogenetics and molecular mutations than are observed in de novo MDS patients. 11, 21 In the present cohort of post-AA MDS patients, the proportion with poor risk cytogenetics was also higher than in patients with de novo MDS, even though prior treatment consisted of IST rather than cytotoxic modalities. This observation suggests the possibility that IST and, possibly, factors predisposing to AA, contributed to the evolution of the karyotype. However, the overall outcome of post-AA MDS was comparable to that of de novo MDS and likely better than the outcome in patients with MDS evolving after chemo-or radiotherapy as observed in prior studies. to induce remission), and it is likely that patients considered to be at the highest risk of relapse were the most likely to receive pre-HSCT chemotherapy. Further, a recent analysis in a large cohort of unselected patients with MDS showed that pre-transplant chemotherapy was an adverse risk factor for post-HSCT outcome. 22 . 23 These data, therefore, suggest some differences compared to results in patients with MDS after cytotoxic chemotherapy or radiotherapy, where outcome was strictly related to the karyotype.
10,11
The present results do raise questions in regards to the timing of HSCT in patients with AA. In summary, patients who developed MDS following IST for AA had a probability of survival similar to patients with de novo MDS. Long-term survival may be slightly better than among patients with treatment-related MDS following cytotoxic therapy.
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